Siemens To Showcase Its Nuclear Medicine Innovations At BNMS 2009 - Biograph MCT And IQ.SPECT Technology Highlight Portfolio Of Advanced Offerings

Main Category: Radiology / Nuclear Medicine
Also Included In: MRI / PET / Ultrasound;  Medical Devices / Diagnostics;  Conferences
Article Date: 12 Mar 2009 - 6:00 PDT

email to a friend   printer friendly   view / write opinions

Siemens will be presenting its latest product advancements at the British Nuclear Medicine Society's Annual Meeting from the 27 - 29 April 2009 at the Manchester Central Convention Complex. This includes information on its innovation, the Biograph™ mCT for molecular Computed Tomography as well as the Symbia® T16 TruePoint SPECT.CT and the world's first intelligent SPECT technology, IQ.SPECT. Siemens will also be offering information from PETNET Solutions, its PET tracer division that supplies biomarkers for imaging.

The newly launched Biograph mCT integrates the first advanced HD•PET platform and the world's first Adaptive Spiral CT to create a next generation dual modality device for a new level of integrated imaging. It can offer whole body scans in five minutes at an ultra low dose for the optimum workflow efficiency. With Biograph mCT, a single room can be transformed into a fast, dual-modality scanning facility, where both CT and PET can be operated in one room with one clinician, one schedule and if required, one exam. By using a single scanner, hospitals can also be assured of a return on investment whilst providing a more efficient service that strengthens the existing workflow between radiology and molecular imaging departments.

At the stand, PETNET Solutions will also be providing information on its range of PET radiopharmaceuticals for imaging. Equipped to meet the evolving needs of molecular imaging, PETNET Solutions delivers innovative products and services to optimise the value of diagnostic scanning services.

Other innovative product offerings from Siemens include the Symbia T16 TruePoint SPECT•CT that combines a variable angle dual detector SPECT with a 16-slice CT for rapid, accurate attenuation correction, precise localisation and advanced options for cardiology including calcium scoring in 15-20 seconds. Siemens will also be offering information on the world's first intelligent SPECT technology, IQ•SPECT, for improved image quality in clinically challenging situations. When combined with the Symbia S and Symbia T series systems, IQ•SPECT is able to provide more information on the heart in five minutes, in comparison to 20 minutes using traditional SPECT.

"Siemens is leading the way in nuclear medicine innovation and new product offerings such as the Biograph mCT highlight our commitment to deliver evolving solutions that benefit both staff and patient," said Lawrence Foulsham, Product Manager for Molecular Imaging and Oncology at Siemens Healthcare. "True dual modality imaging is ideal for today's healthcare budgets and offers not only the latest technology but also provides a more comfortable experience for the patient."

The Siemens exhibition will be located at stand number 24, where Symbia and Cyclotron models will be on show. Siemens representatives will be available on the stand to answer questions and discuss the evolving portfolio of nuclear medicine innovations, including imaging technology and biomarker solutions.

About Siemens Healthcare

The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry. The company is a renowned medical solutions provider with core competence and innovative strength in diagnostic and therapeutic technologies as well as in knowledge engineering, including information technology and system integration. With its laboratory diagnostics acquisitions, Siemens Healthcare is the first integrated healthcare company, bringing together imaging and lab diagnostics, therapy and healthcare information technology solutions, supplemented by consulting and support services. Siemens Healthcare delivers solutions across the entire continuum of care - from prevention and early detection, to diagnosis, therapy and care. Additionally, Siemens Healthcare is the global market leader in innovative hearing instruments. The company employs more than 49,000 people worldwide and operates in 130 countries. In the fiscal year 2008 (Sept. 30), Siemens Healthcare reported sales of €11.2 billion, orders of €11.8 billion, and Sector profit of €1.2 billion. Further information can be found by visiting http://www.siemens.co.uk/healthcare.

Siemens Healthcare